M. D. Galsky Et Al. , "Characterization of complete responders to nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial," JOURNAL OF CLINICAL ONCOLOGY , no.16, 2024
Galsky, M. D. Et Al. 2024. Characterization of complete responders to nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial. JOURNAL OF CLINICAL ONCOLOGY , no.16 .
Galsky, M. D., Sonpavde, G. P., Powles, T., Claps, M., Burotto, M., Schenker, M., ... Sade, J. P.(2024). Characterization of complete responders to nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial. JOURNAL OF CLINICAL ONCOLOGY , no.16.
Galsky, Matt Et Al. "Characterization of complete responders to nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial," JOURNAL OF CLINICAL ONCOLOGY , no.16, 2024
Galsky, Matt D. Et Al. "Characterization of complete responders to nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial." JOURNAL OF CLINICAL ONCOLOGY , no.16, 2024
Galsky, M. D. Et Al. (2024) . "Characterization of complete responders to nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial." JOURNAL OF CLINICAL ONCOLOGY , no.16.
@article{article, author={Matt D. Galsky Et Al. }, title={Characterization of complete responders to nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2024}